MRNA
$42.23
Moderna
$2.12
5.29%
MRNA
Earnings Whisper ®
N/A
1st Quarter March 2026
Consensus:  ($2.10)
Revenue:  N/A
Friday
Feb 13
0:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when MRNA reports earnings?
Beat
Meet
Miss

Where is MRNA's stock price going from here?
Up
Flat
Down
Stock chart of MRNA
Analysts
Summary of analysts' recommendations for MRNA
Score
Grade
Pivots
Resistance
$47.89
$46.34
$44.29

$42.74

Support
$40.69
$39.14
$37.09
Tweet
Growth
Description
Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency use in several countries as COVID-19 vaccine. The company has also developed booster doses of its COVID-19 vaccine and is developing variant-specific booster candidates.